ObsEva SA (NASDAQ:OBSV) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapies in women’s reproductive health and pregnancy. The company focuses on addressing unmet needs in fertility, pregnancy maintenance, and gynecological conditions through precision targeting of hormonal pathways. ObsEva’s research programs are designed to improve outcomes for patients facing endometriosis, uterine fibroids, preterm birth risk, and in vitro fertilization (IVF) challenges.
The company’s lead candidate, nolasiban, is a selective oxytocin receptor antagonist being evaluated to enhance embryo implantation in IVF procedures. In parallel, ObsEva is advancing linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of uterine fibroids and endometriosis. Other pipeline assets include oral progesterone modulators aimed at preventing preterm labor and supporting early pregnancy. ObsEva has entered strategic alliances to support pivotal clinical trials and expedite regulatory submissions.
Headquartered in Geneva, Switzerland, with a U.S. presence in Boston, ObsEva maintains a global operational footprint that spans Europe, North America, and select emerging markets. The company collaborates with academic centers, clinical research organizations, and regional partners to facilitate patient recruitment, trial execution, and regulatory engagement. These collaborations support ObsEva’s goal of delivering data-driven solutions and ensuring broad access to its investigational therapies.
Founded in 2012, ObsEva is led by a management team and board of directors with extensive experience in reproductive science, endocrinology, and biopharmaceutical development. The company’s leadership combines deep scientific expertise with a track record of navigating complex clinical and regulatory pathways. ObsEva continues to pursue clinical milestones and strategic partnerships to bring its innovative reproductive health treatments to market and improve outcomes for women worldwide.
AI Generated. May Contain Errors.
